Ibutamoren (MK-677) versus anabolic steroids: comparing risks
Ibutamoren, known by its development code MK-677, is frequently marketed as a gentler alternative to anabolic steroids. The two work through completely different mechanisms and carry different risk profiles. This editorial overview compares them honestly, without endorsing either, so readers understand what the evidence actually says.
Two different mechanisms
The first thing to understand is that ibutamoren is not a steroid and does not act on the androgen receptor at all. It is a growth-hormone secretagogue: it mimics the hormone ghrelin and stimulates the pituitary gland to release more of the body's own growth hormone and, consequently, insulin-like growth factor 1 (IGF-1). Anabolic-androgenic steroids, by contrast, are synthetic relatives of testosterone that act directly on androgen receptors.
This difference in mechanism matters for everything downstream. Because they work through different hormonal pathways, their effects and their risks diverge considerably. Comparing them is less like comparing two versions of the same drug and more like comparing two entirely different interventions that happen to share a marketing niche.
Neither is an approved medicine for muscle building. Ibutamoren was investigated for conditions such as muscle wasting and growth-hormone deficiency but was not brought to market. Anabolic steroids have legitimate, narrow medical uses but are controlled substances when used for performance or physique. Both are prohibited in sport.
This article compares risks; it does not provide dosing, cycles, stacking or sourcing information for either. The aim is to correct the common but misleading claim that one is simply a "safe version" of the other.
What ibutamoren does
By stimulating growth-hormone release, ibutamoren raises levels of growth hormone and IGF-1. In studies, this increased lean body mass and, notably, body water. Some research in older adults examined its effects on muscle and bone, and a trial in people with hip fracture explored functional outcomes. Reported effects also include increased appetite — a consequence of its ghrelin-mimicking action.
The side-effect profile seen in research reflects the hormones it elevates. Common effects include fluid retention, joint pain, increased appetite and, importantly, effects on blood sugar: growth hormone opposes insulin, so ibutamoren can raise fasting glucose and reduce insulin sensitivity. This is a meaningful concern, particularly for anyone at risk of diabetes.
A commonly overlooked point is that elevating growth hormone and IGF-1 chronically is not without theoretical risk. IGF-1 influences cell growth, and sustained high levels raise questions about long-term effects that the short trials of ibutamoren were not designed to answer. The absence of long-term human safety data is a genuine limitation.
Because ibutamoren does not suppress the body's testosterone in the way steroids do, its advocates present it as "non-suppressive". That is true of the testosterone axis specifically, but it does not make the compound risk-free; it simply shifts the risks elsewhere — to glucose metabolism, fluid balance and the unknowns of chronic growth-hormone elevation.
What anabolic steroids do
Anabolic-androgenic steroids act directly on androgen receptors to increase muscle protein synthesis and strength. Their effects on physique are more pronounced and more reliable than those of ibutamoren, which is part of why they remain in use despite their risks. But those risks are substantial and well documented.
The Endocrine Society's scientific statement catalogues the harms: suppression of the body's own testosterone production (leading to testicular shrinkage and infertility), adverse effects on cholesterol and the cardiovascular system including heart muscle changes, mood disturbance, and — for oral 17-alkylated steroids — liver strain. In women, virilising effects such as voice deepening can be permanent.
Cardiovascular risk is perhaps the most serious concern with long-term steroid use, with studies describing changes in heart structure and function and unfavourable lipid profiles. The suppression of natural testosterone is another defining feature, sometimes requiring prolonged recovery and occasionally failing to resolve fully.
So the steroid side of the comparison brings stronger physique effects but a heavier and better-characterised burden of serious risk, concentrated in the cardiovascular, hepatic and endocrine systems. These are not hypothetical; they are documented across decades of clinical literature.
A useful reference here is farmacia atletica web oficial.
A side-by-side comparison of risks
Placing the two next to each other clarifies that "which is safer" is the wrong question. They carry different risks, some of which are better understood than others. The table summarises the principal concerns, drawn from the published literature.
| Concern | Ibutamoren (MK-677) | Anabolic steroids |
|---|---|---|
| Mechanism | ↑ growth hormone / IGF-1 | Androgen receptor agonism |
| Testosterone suppression | Not characteristic | Characteristic and significant |
| Blood sugar / insulin | Reduced insulin sensitivity | Variable, usually less direct |
| Fluid / joints | Retention, joint pain common | Fluid retention possible |
| Cardiovascular | Less characterised; theoretical | Well-documented adverse effects |
| Liver (oral AAS) | Not a defining feature | 17-alkylated orals strain the liver |
| Long-term human data | Very limited | More extensive, mostly adverse |
The honest reading of this table is that steroids have the heavier, better-documented risk burden, while ibutamoren's risks are different in kind and poorly characterised over the long term. "Less documented harm" is not the same as "proven safe"; it often reflects a lack of research rather than an absence of risk.
Both share a critical practical hazard: when obtained from unregulated sources, products may be mislabelled, underdosed, overdosed or contaminated. Independent testing of the SARM and research-chemical market has repeatedly found products that do not match their labels, which adds unpredictability on top of the inherent pharmacological risks.
Legal status and the "safer" myth
In the UK, anabolic steroids are Class C controlled substances; possession for personal use is not an offence but supply is. Ibutamoren is not an approved medicine and cannot lawfully be sold for human consumption; the MHRA has warned about products marketed as bodybuilding aids containing unlicensed active substances. Both are prohibited in sport under the World Anti-Doping Code.
The marketing of ibutamoren as a "safe alternative" to steroids is the central myth this comparison is meant to dispel. It is safer in one specific respect — it does not suppress testosterone the way steroids do — but it introduces its own risks around glucose metabolism and carries a near-total absence of long-term human safety data.
- Different, not safer: the risk profiles diverge rather than one being universally milder.
- Glucose matters: ibutamoren's effect on insulin sensitivity is a real concern.
- Unknowns dominate: long-term effects of chronic GH/IGF-1 elevation are unstudied.
- Unregulated market: product quality cannot be assumed for either.
For anyone with a genuine medical reason to consider growth-hormone or androgen therapy, licensed and monitored treatments exist and should be discussed with an endocrinologist. Substituting an unapproved research chemical or a controlled steroid for proper medical care exchanges a supervised, monitored intervention for an unpredictable one.
The reasonable conclusion is to treat the "safer alternative" framing with scepticism. The appropriate comparison is not between two routes to the same goal but between two sets of real risks, neither of which is trivial.
Conclusions of the editorial team
Ibutamoren and anabolic steroids are not two versions of the same thing. One raises the body's own growth hormone and IGF-1 with notable effects on appetite, fluid and blood sugar; the other acts on androgen receptors with stronger physique effects and a heavier, better-documented burden of cardiovascular, hepatic and endocrine harm.
Calling ibutamoren "safer" oversimplifies. It avoids one category of steroid risk while adding others and leaving long-term questions unanswered. The responsible framing is that both carry real, different risks and that neither belongs in casual, unsupervised use.
Readers may also find our material on growth hormone physiology, on the documented risks of anabolic steroids, and on why the SARM and research-chemical market is so unreliable helpful alongside this comparison.
References
- Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Ann Intern Med. 2008;149(9):601–611.
- Murphy MG, Weiss S, McClung M, et al. Effect of the oral growth hormone secretagogue MK-677 on bone metabolism. J Clin Endocrinol Metab. 2001;86(3):1116–1125.
- Pope HG Jr, Wood RI, Rogol A, et al. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev. 2014;35(3):341–375.
- Baggish AL, Weiner RB, Kanayama G, et al. Cardiovascular toxicity of illicit anabolic-androgenic steroid use. Circulation. 2017;135(21):1991–2002.
- Van Wagoner RM, Eichner A, Bhasin S, et al. Chemical composition and labeling of substances marketed as SARMs. JAMA. 2017;318(20):2004–2010.
- Medicines and Healthcare products Regulatory Agency. Warning on unlicensed bodybuilding products. London: MHRA; 2021.
